KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash & Equivalents (2019 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Cash & Equivalents for 5 consecutive years, with $1.0 billion as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Cash & Equivalents fell 19.45% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Sep 2023, down 19.45%, and an annual FY2022 reading of $1.3 billion, down 15.11% over the prior year.
  • Cash & Equivalents was $1.0 billion for Q3 2023 at Ginkgo Bioworks Holdings, down from $1.1 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.8 billion in Q3 2021 and bottomed at $235.9 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $1.0 billion, with a median of $1.2 billion recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 483.8% in 2022, while the deepest fall reached 26.21% in 2022.
  • Year by year, Cash & Equivalents stood at $495.3 million in 2019, then decreased by 23.12% to $380.8 million in 2020, then surged by 307.04% to $1.6 billion in 2021, then fell by 15.11% to $1.3 billion in 2022, then fell by 20.26% to $1.0 billion in 2023.
  • Business Quant data shows Cash & Equivalents for DNA at $1.0 billion in Q3 2023, $1.1 billion in Q2 2023, and $1.2 billion in Q1 2023.